We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New AI Blood Test Could Become Game Changer for Bowel Cancer Diagnosis

By LabMedica International staff writers
Posted on 10 Mar 2023
Print article
Image: A fast, inexpensive and scalable test for the early diagnosis of bowel cancer is currently under development (Photo courtesy of Pexels)
Image: A fast, inexpensive and scalable test for the early diagnosis of bowel cancer is currently under development (Photo courtesy of Pexels)

Colorectal cancer (CRC), also referred to as bowel cancer, is the world's third most common cancer and the fourth leading cause of death. It is responsible for approximately 1.4 million new cases and 700,000 deaths every year. In Europe, bowel cancer is the second most prevalent cancer, with 450,000 cases annually. Developed countries have seen an increase in incidence of CRC, and the figures remain high. Early detection of CRC has always been crucial in saving lives. Now, the introduction of a fast, affordable, and scalable test for the early detection of bowel cancer could revolutionize the approach to the diagnosis and screening of this disease.

CanSense Ltd. (Swansea, UK) is harnessing artificial intelligence-based modeling (AI) to create a rapid, affordable, and versatile test that can detect bowel cancer in its early stages, save lives and reduce distress. The test could help dramatically reduce the mortality rate of CRC via early stage diagnosis. It also has the potential to reduce the need for unnecessary invasive colonoscopies and the associated financial burden on healthcare providers.

Negative colonoscopy procedures are associated with considerable economic costs, estimated to be a minimum of USD 4.2 billion worldwide. The blood test can serve as a tool to aid healthcare professionals in determining the necessity of further colonoscopy examinations. From the viewpoint of an anxious symptomatic patient, this approach to CRC triage offers significant advantages. The test can yield quick and accurate results, identifying patients requiring immediate and priority treatment. For those given a negative diagnosis, it effectively eliminates the need for colonoscopy procedures and quickly reduces their anxiety.

Related Links:
CanSense Ltd. 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.